Clinical Trial Update: Evaluation of Dextenza in Patients With Ocular GVHD and Effects on Ocular Surface Disease Outcomes [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating Dextenza for ocular GVHD was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Dextenza (Dexamethasone)

Snippet

Sponsor: Massachusetts Eye and Ear Infirmary | Conditions: Graft Vs Host Disease | Phase 4 | Status: WITHDRAWN